1606 Corp. Price & Performance (CBDW)

Bolt Biotherapeutics reported a first-quarter operating loss of $12.1 million, a marked improvement from $17.1 million a year earlier, driven by lower research and administrative expenses. Collaboration revenue dropped sharply to $1.2 million, but the company’s cash reserves of $58 million are projected to fund operations through mid-2026.12

Grifols posted consolidated Q1 2025 revenue of €1.79 billion, up 7.4% year-over-year, and adjusted EBITDA margin rose to 22.4%. The company’s leverage ratio improved significantly to 4.5x, reflecting progress in reducing debt. Management reaffirmed full-year guidance and emphasized strong liquidity and continued focus on financial discipline.3

1606 Corp. (CBDW) experienced high volatility, swinging 36% intraday on May 9, 2025, but closed unchanged at $0.0064. Despite some positive technical signals, analysts have downgraded the stock to a hold/accumulate rating, citing persistent risks and an expected short-term decline of nearly 19% over the next three months.4